Urologic Oncologist, Zeyad Schwen, MD, joins the Cancer Advances podcast to discuss prostate cancer and genomics. Learn about the latest advancements in genomic testing, its impact on diagnosis and treatment, and how these innovations shape personalized care in oncology. Dr. Schwen shares insights on the practical applications of genomics in prostate cancer, discusses ongoing research, and explores the potential future of cancer diagnostics.

Lukas Delasos, DO, Medical Oncologist at Cleveland Clinic, joins the Cancer Advances podcast to talk about the ADRIATRIC study. Dr. Delasos shares his insights on small cell lung cancer, detailing its aggressive nature, current treatment paradigms, and the promising results from the ADRIATIC study involving durvalumab as a consolidation therapy.

The Cancer Advances podcast is joined by Palliative Medicine physicians, Renato Samala, MD and Chirag Patel, MD to discuss the use of scrambler technology to treat neuropathic symptoms in cancer patients. Traditional medications for neuropathic symptoms caused by cancer treatments can be ineffective and often have side effects. Scrambler technology, which uses electrical signals to reprogram nerve signals, offers an innovative alternative. Listen as Dr. Samala and Dr. Patel explain the potential benefits of scrambler therapy, its application, patient selection, and prospects for better access and research on long-term outcomes.

Joel Cardenas Goicoechea, MD, MBA, a Gynecologic Oncologist at Cleveland Clinic Weston Hospital in Florida, joins the Cancer Advances podcast to discuss the benefits of robotic cytoreductive surgery combined with laparoscopic HIPEC for ovarian cancer. Listen as Dr. Cardenas explains how this innovative approach offers lower complication risks, reduced blood loss, and shorter hospital stays than traditional open surgery. Tune in to learn how these advancements enhance patient outcomes and quality of life in the treatment of ovarian cancer.

Gynecologic Oncologist, Peter Rose, MD, joins the Cancer Advances podcast to share insights on an exciting new clinical trial investigating adoptive immunotherapy for ovarian cancer. The trial investigates personalized T-cell therapies and their potential to transform treatment outcomes. Discover how this groundbreaking approach offers new hope in the battle against advanced ovarian cancer.

Holly Pederson, MD, an Oncologist and member of the medical breast team at Cleveland Clinic, joins the Cancer Advances podcast to discuss her research on using polygenic risk scores to predict early onset triple-negative breast cancer in Black women. While polygenic risk scores have shown promise in predicting breast cancer risk, they have mainly been tested in European women and are less accurate for other ancestries. Listen as Dr. Pederson talks about the complexities of genetic risk factors across different ancestries and how these scores can revolutionize early detection and prevention strategies.

The Cancer Advances podcast is joined by Wen Wee Ma, MBBS, Director of the Novel Cancer Therapeutics Center, and Lucy Boyce Kennedy, MD, Director of the Oncology Pharmacovigilance Clinic. Listen as they discuss how this new Oncology Pharmacovigilance Clinic enhances patient care by addressing complex toxicities and side effects from immunotherapy treatment, and integrates specialists from rheumatology, endocrinology, pulmonology and more.

Nima Almassi, MD, a Urologic Oncologist at Cleveland Clinic, joins the Cancer Advances Podcast to discuss managing non-muscle-invasive bladder cancer with variant histologies. Listen as Dr. Almassi talks about effectiveness of intravesical therapy, the importance of specialized pathology reviews, and the potential need for early cystectomy in aggressive variants.

Roberto Vargas, MD, gynecologic oncologist at Cleveland Clinic, joins the Cancer Advances Podcast to discuss adding immunotherapy to chemotherapy for endometrial cancer. Listen as Dr. Vargas sheds light on recent studies demonstrating that adding checkpoint inhibitors to standard chemotherapy could notably lower the risk of cancer recurrence in patients with MMR-deficient or MSI-high tumors and the potential of genomic-based therapies for endometrial cancers.

Erin Murphy, MD, Director of Pediatric Radiation Oncology at Cleveland Clinic, joins the Cancer Advances Podcast to discuss stereotactic radio surgery (SRS) for adolescent and young adult brain and spine tumors. Listen as Dr. Murphy highlights the benefits of SRS for younger patients, including shorter treatment intervals, less impact on daily routine and recovery, and the ability to continue with school during treatment.